BioSpace News Archive

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment Data presented today in a late-breaking oral presentation at AAD VMX 2021 Management to host an investor call today at 12:00 p.m. EDT

Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentation Data demonstrate roflumilast foam was well-tolerated and improved scalp and body psoriasis as early as two weeks after treatment initiation Four additional posters feature data that support roflumilast foam for the treatment of seborrheic dermatitis and roflumilast cream for mild-to- severe chronic plaque psoriasis

The AAD VMX 2021, a virtual meeting experience taking place April 23-25, will feature the latest information on skin, hair and nails, presented by world-renowned experts in the field of dermatology.

Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings

Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing.

Ethypharm announces that it now has a fully established affiliate to operate directly in Italy, the third largest pharmaceutical market in Europe.

Boehringer Ingelheim today announced results from a phase III, randomized study that concluded that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate-to-severe chronic plaque psoriasis.

Skin clearance rates were maintained at five years with 55.5 percent of patients achieving an Investigator’s Global Assessment score of 0 and 53 percent achieving Psoriasis Area Severity Index 100 response in VOYAGE 2

Taltz also helped patients stay on treatment longer and have more days without additional therapy in three real-world analyses of U.S. claims data

Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte’s (NASDAQ:INCY) OLUMIANT®